Identification

Name
Cyclandelate
Accession Number
DB04838
Type
Small Molecule
Groups
Approved
Description

A direct-acting smooth muscle relaxant used to dilate blood vessels. It may cause gastrointestinal distress and tachycardia. Cyclandelate is not approved for use in the U.S. or Canada, but is approved in various European countries.

Structure
Thumb
Synonyms
  • 3,3,5-Trimethylcyclohexyl mandelate
  • 3,5,5-Trimethylcyclohexyl amygdalate
  • Ciclandelato
  • Cyclandelatum
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cyclospasmol Tablets 200mgTablet200 mgOralWyeth Ayerst Canada Inc.1994-12-311997-08-14Canada
International/Other Brands
Capilan (Takeda) / Cyclergine / Cyclospasmol (lves)
Categories
UNII
4139O1OAY2
CAS number
456-59-7
Weight
Average: 276.3707
Monoisotopic: 276.172544634
Chemical Formula
C17H24O3
InChI Key
WZHCOOQXZCIUNC-UHFFFAOYSA-N
InChI
InChI=1S/C17H24O3/c1-12-9-14(11-17(2,3)10-12)20-16(19)15(18)13-7-5-4-6-8-13/h4-8,12,14-15,18H,9-11H2,1-3H3
IUPAC Name
3,3,5-trimethylcyclohexyl 2-hydroxy-2-phenylacetate
SMILES
CC1CC(CC(C)(C)C1)OC(=O)C(O)C1=CC=CC=C1

Pharmacology

Indication

Used in the treatment of various blood vessel diseases (e.g., claudication, arteriosclerosis and Raynaud's disease) and nighttime leg cramps.

Pharmacodynamics

Cyclandelate is in a class of drugs called vasodilators. Cyclandelate relaxes veins and arteries, which makes them wider and allows blood to pass through them more easily.

Mechanism of action

Cyclandelate produces peripheral vasodilation by a direct effect on vascular smooth muscle. Pharmacological action may be due to calcium-channel antagonism.

TargetActionsOrganism
UVoltage-dependent calcium channel subunit alpha-2/delta-1
inhibitor
Human
ULiver carboxylesterase 1Not AvailableHuman
Absorption

Well absorbed following oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Acute oral toxicity (LD50): 3950 mg/kg [Guinea pig]

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Cyclandelate.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Cyclandelate.Vet Approved
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Cyclandelate.Approved, Vet Approved
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Cyclandelate.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Cyclandelate.Approved
AmobarbitalThe metabolism of Cyclandelate can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Cyclandelate.Approved, Investigational
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Cyclandelate.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be increased when used in combination with Cyclandelate.Approved, Investigational
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Cyclandelate.Approved, Investigational
AripiprazoleThe risk or severity of hypotension can be increased when Aripiprazole is combined with Cyclandelate.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Cyclandelate.Investigational
ArtemetherThe therapeutic efficacy of Artemether can be increased when used in combination with Cyclandelate.Approved
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Cyclandelate.Approved
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Cyclandelate.Experimental
BarbexacloneThe metabolism of Cyclandelate can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Cyclandelate can be increased when combined with Barbital.Illicit
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Cyclandelate.Approved, Investigational
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Cyclandelate.Approved
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Cyclandelate.Approved, Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Cyclandelate.Experimental
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Cyclandelate.Approved, Investigational
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Cyclandelate.Investigational
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Cyclandelate.Investigational
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Cyclandelate.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Cyclandelate.Approved
Calcium AcetateThe therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Cyclandelate.Withdrawn
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Cyclandelate.Experimental
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Cyclandelate.Approved, Investigational
CaseinThe therapeutic efficacy of Cyclandelate can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Cyclandelate.Approved
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Cyclandelate.Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Cyclandelate.Approved
ChlorpromazineThe risk or severity of hypotension can be increased when Chlorpromazine is combined with Cyclandelate.Approved, Investigational, Vet Approved
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Cyclandelate.Approved, Investigational
CimetidineThe serum concentration of Cyclandelate can be increased when it is combined with Cimetidine.Approved, Investigational
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Cyclandelate.Approved
ClotrimazoleThe therapeutic efficacy of Clotrimazole can be increased when used in combination with Cyclandelate.Approved, Vet Approved
ClozapineThe risk or severity of hypotension can be increased when Clozapine is combined with Cyclandelate.Approved
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Cyclandelate.Investigational
CyclosporineThe therapeutic efficacy of Cyclosporine can be increased when used in combination with Cyclandelate.Approved, Investigational, Vet Approved
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Cyclandelate.Approved
DextroamphetamineThe risk or severity of hypotension can be increased when Dextroamphetamine is combined with Cyclandelate.Approved, Illicit
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Cyclandelate.Vet Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Cyclandelate.Approved
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Cyclandelate.Approved, Investigational
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Cyclandelate.Approved
DroperidolThe risk or severity of hypotension can be increased when Droperidol is combined with Cyclandelate.Approved, Vet Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Cyclandelate.Approved
EfavirenzThe serum concentration of Cyclandelate can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Cyclandelate.Approved
EpinephrineThe risk or severity of hypotension can be increased when Epinephrine is combined with Cyclandelate.Approved, Vet Approved
EscitalopramThe risk or severity of hypotension can be increased when Escitalopram is combined with Cyclandelate.Approved, Investigational
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Cyclandelate.Experimental
FluconazoleThe therapeutic efficacy of Fluconazole can be increased when used in combination with Cyclandelate.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Cyclandelate.Approved, Investigational
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Cyclandelate.Approved, Investigational, Withdrawn
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Cyclandelate.Experimental
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Cyclandelate.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Cyclandelate.Approved, Investigational, Vet Approved
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Cyclandelate.Experimental
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Cyclandelate.Approved, Withdrawn
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Cyclandelate.Approved, Investigational
HexobarbitalThe metabolism of Cyclandelate can be increased when combined with Hexobarbital.Approved
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Cyclandelate.Approved
ImipramineThe risk or severity of hypotension can be increased when Imipramine is combined with Cyclandelate.Approved
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Cyclandelate.Withdrawn
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Cyclandelate.Approved
ItraconazoleThe therapeutic efficacy of Itraconazole can be increased when used in combination with Cyclandelate.Approved, Investigational
KetoconazoleThe therapeutic efficacy of Ketoconazole can be increased when used in combination with Cyclandelate.Approved, Investigational
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Cyclandelate.Approved
LisdexamfetamineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Cyclandelate.Approved, Investigational
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Cyclandelate is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Cyclandelate is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Cyclandelate is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Cyclandelate is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Cyclandelate.Experimental
MethohexitalThe metabolism of Cyclandelate can be increased when combined with Methohexital.Approved
MethotrimeprazineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Cyclandelate.Approved, Investigational
MethylphenobarbitalThe metabolism of Cyclandelate can be increased when combined with Methylphenobarbital.Approved
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Cyclandelate.Experimental
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Cyclandelate.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Cyclandelate.Approved, Investigational, Vet Approved
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Cyclandelate.Approved, Investigational
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Cyclandelate.Vet Approved
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Cyclandelate.Experimental
NafcillinThe therapeutic efficacy of Cyclandelate can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Cyclandelate.Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Cyclandelate.Approved
NefazodoneThe risk or severity of hypotension can be increased when Nefazodone is combined with Cyclandelate.Approved, Withdrawn
NicardipineThe risk or severity of hypotension can be increased when Nicardipine is combined with Cyclandelate.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Cyclandelate.Approved, Investigational
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Cyclandelate.Experimental
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Cyclandelate.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Cyclandelate.Investigational
NitroprussideCyclandelate may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Cyclandelate.Approved
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Cyclandelate.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Cyclandelate.Approved, Vet Approved
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Cyclandelate.Approved, Investigational
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Cyclandelate.Experimental
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Cyclandelate.Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Cyclandelate.Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Cyclandelate.Approved
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Cyclandelate.Approved, Investigational
PentobarbitalThe metabolism of Cyclandelate can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PhenobarbitalThe metabolism of Cyclandelate can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Cyclandelate.Approved
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Cyclandelate.Approved
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Cyclandelate.Approved
PosaconazoleThe therapeutic efficacy of Posaconazole can be increased when used in combination with Cyclandelate.Approved, Investigational, Vet Approved
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Cyclandelate.Approved
PrimidoneThe metabolism of Cyclandelate can be increased when combined with Primidone.Approved, Vet Approved
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Cyclandelate.Approved, Vet Approved
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Cyclandelate.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Cyclandelate.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Cyclandelate.Approved, Investigational
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Cyclandelate.Experimental
QuetiapineThe risk or severity of hypotension can be increased when Quetiapine is combined with Cyclandelate.Approved
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Cyclandelate.Approved, Investigational
RacepinephrineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Cyclandelate.Approved
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Cyclandelate.Experimental
RifabutinThe risk or severity of hypotension can be increased when Rifabutin is combined with Cyclandelate.Approved, Investigational
RifampicinThe risk or severity of hypotension can be increased when Rifampicin is combined with Cyclandelate.Approved
RifapentineThe risk or severity of hypotension can be increased when Rifapentine is combined with Cyclandelate.Approved, Investigational
RifaximinThe risk or severity of hypotension can be increased when Rifaximin is combined with Cyclandelate.Approved, Investigational
RisperidoneThe risk or severity of hypotension can be increased when Risperidone is combined with Cyclandelate.Approved, Investigational
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Cyclandelate.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Cyclandelate.Approved, Investigational, Vet Approved
SecobarbitalThe metabolism of Cyclandelate can be increased when combined with Secobarbital.Approved, Vet Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Cyclandelate.Approved, Investigational
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Cyclandelate.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Cyclandelate.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Cyclandelate.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Cyclandelate.Approved
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Cyclandelate.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Cyclandelate.Approved, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Cyclandelate.Approved
TerbinafineThe therapeutic efficacy of Terbinafine can be increased when used in combination with Cyclandelate.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Cyclandelate.Approved
ThiamylalThe metabolism of Cyclandelate can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Cyclandelate can be increased when combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Cyclandelate.Approved
ThioridazineThe risk or severity of hypotension can be increased when Thioridazine is combined with Cyclandelate.Approved, Withdrawn
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Cyclandelate.Approved
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Cyclandelate.Approved
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Cyclandelate.Approved, Vet Approved
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Cyclandelate.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Cyclandelate.Approved, Investigational, Vet Approved
TrazodoneThe risk or severity of hypotension can be increased when Trazodone is combined with Cyclandelate.Approved, Investigational
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Cyclandelate.Approved, Investigational
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Cyclandelate.Experimental
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Cyclandelate.Approved, Investigational
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Cyclandelate.Approved
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Cyclandelate.Investigational
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Cyclandelate.Approved
VoriconazoleThe therapeutic efficacy of Voriconazole can be increased when used in combination with Cyclandelate.Approved, Investigational
WortmanninThe therapeutic efficacy of Wortmannin can be increased when used in combination with Cyclandelate.Experimental
ZiprasidoneThe risk or severity of hypotension can be increased when Ziprasidone is combined with Cyclandelate.Approved
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Cyclandelate.Approved, Investigational
Food Interactions
  • Take with food to reduce irritation.

References

Synthesis Reference

Nauta, W.T.; U.S. Patent 2,707,193; April 26,1955; assigned to N.V. Koninklijke Pharmaceutische Fabrieken Voorbeen Brocades Stheeman & Pharmacia, Netherlands. Flitter, D.; U.S. Patent 3,663,597; May 16, 1972; assigned to American Home Products Corporation.

General References
Not Available
External Links
Human Metabolome Database
HMDB0015586
PubChem Compound
2893
PubChem Substance
46505740
ChemSpider
2790
ChEBI
3988
ChEMBL
CHEMBL1480987
PharmGKB
PA164748026
Drugs.com
Drugs.com Drug Page
Wikipedia
Cyclandelate
ATC Codes
C04AX01 — Cyclandelate
MSDS
Download (73.8 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Spectrum Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral200 mg
Prices
Unit descriptionCostUnit
Cyclandelate powder8.18USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)50-53Nauta, W.T.; U.S. Patent 2,707,193; April 26,1955; assigned to N.V. Koninklijke Pharmaceutische Fabrieken Voorbeen Brocades Stheeman & Pharmacia, Netherlands.
boiling point (°C)193 °C at 1.40E+01 mm HgPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.0997 mg/mLALOGPS
logP3.79ALOGPS
logP3.72ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)11.99ChemAxon
pKa (Strongest Basic)-4.1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity78.06 m3·mol-1ChemAxon
Polarizability30.95 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9925
Blood Brain Barrier+0.8761
Caco-2 permeable+0.7443
P-glycoprotein substrateNon-substrate0.551
P-glycoprotein inhibitor IInhibitor0.6324
P-glycoprotein inhibitor IINon-inhibitor0.6209
Renal organic cation transporterNon-inhibitor0.8746
CYP450 2C9 substrateNon-substrate0.7769
CYP450 2D6 substrateNon-substrate0.9047
CYP450 3A4 substrateSubstrate0.6148
CYP450 1A2 substrateNon-inhibitor0.8485
CYP450 2C9 inhibitorInhibitor0.7116
CYP450 2D6 inhibitorNon-inhibitor0.9365
CYP450 2C19 inhibitorNon-inhibitor0.7518
CYP450 3A4 inhibitorNon-inhibitor0.9024
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9469
Ames testNon AMES toxic0.8703
CarcinogenicityNon-carcinogens0.7047
BiodegradationNot ready biodegradable0.9626
Rat acute toxicity1.7115 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9942
hERG inhibition (predictor II)Non-inhibitor0.8132
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Not Available
Direct Parent
Benzene and substituted derivatives
Alternative Parents
Secondary alcohols / Carboxylic acid esters / Monocarboxylic acids and derivatives / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds / Aromatic alcohols
Substituents
Monocyclic benzene moiety / Secondary alcohol / Carboxylic acid ester / Monocarboxylic acid or derivatives / Carboxylic acid derivative / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Aromatic alcohol / Organooxygen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
carboxylic ester, secondary alcohol (CHEBI:3988)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-...
Gene Name
CACNA2D1
Uniprot ID
P54289
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-1
Molecular Weight
124566.93 Da
References
  1. Pascual J: [New prospects in the treatment of migraine]. Neurologia. 1999 Dec;14 Suppl 6:26-35. [PubMed:10659603]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Triglyceride lipase activity
Specific Function
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acy...
Gene Name
CES1
Uniprot ID
P23141
Uniprot Name
Liver carboxylesterase 1
Molecular Weight
62520.62 Da
References
  1. Heffron F, Middleton B, White DA: Inhibition of acyl coenzyme A: cholesterol acyl transferase by trimethylcyclohexanylmandelate (cyclandelate). Biochem Pharmacol. 1990 Feb 1;39(3):575-80. [PubMed:2306268]

Drug created on September 26, 2007 09:09 / Updated on July 02, 2018 18:22